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Abstract
Background: The critical role of the immune system in controlling cancer progression has become evident and
immune modulatory therapy is now approved for clinical use. However, while the majority of studies on the
inflammatory tumour microenvironment have focused on the cellular immune response, in particular the
prognostic and predictive role of various T cell infiltrates, the role of the humoral immune response in this context
has long been overlooked. This study aimed to investigate the clinicopathological correlates and prognostic impact
of B cell and plasma cell infiltration in epithelial ovarian cancer (EOC).
Methods: Immunohistochemical expression of immunoglobulin kappa C (IGKC), CD20 and CD138 was analysed in
tissue microarrays with tumours from 154 incident cases of EOC from two pooled prospective population-based
cohorts. Subsets of corresponding benign-appearing fallopian tubes (n = 38) and omental metastases (n = 33) were
also analysed. Kaplan-Meier analysis and Cox regression analysis were used to determine the impact of immune-cell
specific IGKC, CD20 and CD138 expression on overall survival and ovarian cancer-specific survival.
Results: High IGKC expression correlated significantly with expression of CD20 (p = 0.001) and CD138 (p = 0.035).
Expression of IGKC as well as CD138 was significantly higher in primary tumours than in fallopian tubes (p = 0.004
and p = 0.001, respectively). High CD20 and CD138 expression correlated significantly with high tumour grade
(p = 0.032 and p = 0.030, respectively). CD20 and IGKC expression was not prognostic but univariable Cox
regression analysis revealed high CD138 expression to correlate with a significantly reduced overall survival
(HR = 2.20; 95 % CI 1.34–3.55; p–0.001) as well as ovarian cancer-specific survival (HR = 1.95; 95 % CI 1.28–2.98;
p = 0.002). The prognostic impact was independent of established clinical parameters (age, grade, clinical
stage) as shown in multivariable analysis (HR = 2.28; 95 % CI 1.39–3.75; p = 0.001).
Conclusions: In conclusion, our results demonstrate that plasma cell infiltration in epithelial ovarian cancer
has a significant impact on tumour progression and prognosis. The important role of the humoral immune
system merits further study and may be harnessed as immune modulatory strategies in cancer therapy.
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Background
Cancer immunity has emerged as a clinically relevant
hallmark of cancer biology [1]. The immune system
plays a multifaceted role and may in different contexts
promote or inhibit tumour growth [2]. On the one hand,
inflammation caused by cancer and specific immune cell
infiltrates have demonstrated tumorigenic properties [3].
On the other hand, inflammatory cells, in particular of
the T-cell lineage, are associated with inhibiting properties
and are capable to eliminate tumor cells [4]. As a proof of
concept, so-called checkpoint inhibitors, modulating the
T-cell response, have been shown to impress response
rates in different solid tumours and are now approved for
the treatment of lung cancer and melanoma [5, 6].
Consequently, the majority of studies concerning the
role of the immune system in cancer have focused on
the cellular response. Indeed, high infiltration of specific
T-lymphocytes has been associated with favourable clin-
ical outcome in many tumour types and an immune index
has been suggested to outperform classical prognostic pa-
rameters in colon cancer [7]. The humoral anti-tumour
response, however, has been far less investigated.
Immunoglobulin kappa C (IGKC), expressed in plasma
cells, has in breast cancer been identified as one of the top
genes of a prognostic B cell-metagene [8] and is related to
favourable prognosis and response to chemotherapy [8]. The
auspicious impact of IGKC has been confirmed in non-small
cell lung cancer [9] and colorectal cancer [10] and in the
former study, CD138-expressing plasma cells were identified
as the cellular correlate for the gene expression signature.
Also, in epithelial ovarian cancer (EOC), tumour-
specific CD138 expression has been shown to be associ-
ated with enhanced cell invasion [11] and poor patient
outcome [12, 13]. CD20+ tumour infiltrating lymphocytes
(TILs), i.e. mature B cells who have undergone Ig-class
switching [14], are reportedly strongly linked to an
improved patient outcome in high-grade serous ovarian
cancer when combined with CD8+ T cells [15]. However,
another study, analysing only IGKC mRNA expression,
did not find any correlation with survival [10].
The aim of this study was to examine the immunohisto-
chemical (IHC) expression and clinical correlates of IGKC,
CD20 and CD138 protein expression in tumours from 154
EOC cases from two pooled, prospective, population-based
cohorts. Furthermore, we aimed to investigate if these
markers correlate with expression of the polymeric im-
munoglobulin receptor (PIGR), which has previously been
described as an indicator of a less aggressive tumour
phenotype and improved survival in EOC [16].
Methods
Patients
The study cohort is a merge of all incident cases of EOC
in the two prospective population-based cohorts Malmö
Diet and Cancer Study (MDCS) (n = 101) [17] and
Malmö Preventive Project (MPP) (n = 108) [18] until
December 31st 2007, as previously described [16, 19–22].
Information on vital status and cause of death was
obtained from medical charts and the Swedish Cause-of-
Death Registry up until June 30 2012. After a median
follow-up of 3.00 years (range 0–24.63), 122 patients
(79.2 %) were dead, 112 (72.3 %) from ovarian cancer, and
32 (20.8 %) were alive. All tumours were re-evaluated re-
garding histological subtype and grade, by a senior patholo-
gist (KJ). Tumours were categorised into four groups
according to histological subtype: serous (n = 90), endome-
trioid (n = 35), mucinous (n = 12) and others (n = 17). The
group of others included clear cell (n = 9), Brenner (n = 1)
and unknown (n = 7) tumours. Histopathological, clinical
and treatment data were obtained from clinical and/or path-
ology records. Information on residual tumour after surgery
was not available. Standard adjuvant therapy was platinum-
based chemotherapy in combination with paclitaxel.
Ethical permission for the study was approved by the
Ethics Committee of Lund University (Ref 445/2007).
Tissue microarray construction
Tissue microarrays (TMAs) were constructed as previ-
ously described [16, 19, 22], whereby two 1.0 mm. cores
were taken from viable, non-necrotic primary tumour
areas, and from concomitant peritoneal metastases (n = 34).
Fallopian tubes with no evidence of histological disease
were also sampled from 38 cases.
Immunohistochemical staining and evaluation
For IHC analysis of CD138 and CD20, 4 μm TMA-
sections were pre-treated using ULTRA Cell Condition
Solution 1, pH 8.5 (Ventana Medical Systems, Tucson,
AZ, USA) ULTRA Cell Conditioning (ULTRA CC1), for
heat induced epitope retrieval, and stained with the
ready-to-use monoclonal antibodies CD20cy Clone L6
and CD138 clone MI15 in a Ventana BenchMark stainer
(Ventana Medical Systems Inc.). The antibody-antigen
complex was visualized with ultraView Universal DAB
Detection kit (Ventana Medical Systems, Inc.).
For analysis of IGKC, the TMA slides were manually
deparaffinised in xylene, rehydrated in graded alcohol and
blocked for endogenous peroxidase in 0.3 % hydrogen per-
oxide. For antigen retrieval, the slides were immersed in Cit-
rate Buffer pH 6.7 and microwaved for 15 min. Automated
IHC was performed with the Autostainer Link 48 (Dako;
Glostrup, Copenhagen, Denmark) and a polyclonal rabbit
anti-human kappa light chain antibody (Dako, A019;1:40
000). The slides were incubated with the secondary anti-
body (EnVision™ FLEX, Rabbit/Mouse, K8000, Dako) for
30 min at RT and developed using diaminobenzidine
(DAB). All TMA slides were counterstained with Mayer’s
hematoxylin (Sigma–Aldrich).
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Evaluation of the IHC staining in immune cells was
annotated by two assessors (JB, SL), whereby consensus
for each core was reached in estimated percentage as a
continuous value. The staining intensity was annotated
in categories of 0–2, where 0 = negative, 1 = intermediate
and 2 = strong intensity.
Core score (CS), i.e. a multiplier of intensity and fraction,
was calculated for each individual core assessed for IGKC,
CD20 and CD138 staining and a mean value of the two
corresponding cores was used in the statistical analyses.
For CD138, tumour-specific expression was also anno-
tated, whereby an estimated percentage of stained cells was
reached in estimated percentage groups as follows; negative
(0 %), 1–25 %, 26–50 %, 51–75 % and 76–100 %. Staining
intensity was annotated in groups of 0–3, whereby 0 =
negative, 1 = weak, 2 =moderate and 3 = strong intensity. A
multiplier of intensity and fraction was calculated for each
core and a quotient of the multiplier and fraction of tumour
cells was calculated and used in the analyses.
Analysis of IHC expression of PIGR had been per-
formed as previously described [16]. KRAS mutation sta-
tus had been determined by pyrosequencing as previously
described [23].
Statistical analysis
Mann–Whitney U-test was used to assess distribution
differences in expression of IGKC, CD20 and CD138 in
relation to clinicopathological characteristics and other
investigative biomarkers. Spearmans Rho test was used
to analyse the interrelationship between IGKC, CD20
and CD138. Paired T-test was used to illustrate differ-
ences of biomarker expression in primary tumours,
metastases and fallopian tubes. Classification tree (CRT)
was used to evaluate optimal cut off for dichotomisation
of biomarker expression. Kaplan-Meier analysis and log
rank test were applied to illustrate differences in overall
survival (OS) and ovarian cancer specific survival (OCSS)
with respect to IGKC, CD20 and CD138 expression. Cox
regression proportional hazard models were used to esti-
mate hazard ratios (HRs) for death from EOC or overall
causes according to high and low expression of the inves-
tigative markers in both uni- and multivariable analysis,
adjusted for age, stage and differentiation grade. All calcu-
lations were performed using SPSS version 22.0 (SPSS Inc,
Chicago, IL). All statistical tests were two-sided and p-
values < 0.05 were considered statistically significant.
Results
Distribution of IGKC, CD20 and CD138 expression in
fallopian tubes, EOC and metastases
Quantification of immunohistochemical expression of
IGKC, CD20 and CD138 is illustrated in Fig. 1. IGKC
expression was evaluable in 151 (98.1 %) of the primary
tumours, 33 (97.1 %) of the metastases and in 32
(82.4 %) of the corresponding fallopian tubes. CD20
expression was evaluable in all 154 of the primary
tumours, in 33 (97.1 %) of the metastases and in 34
(89.5 %) of the fallopian tubes. Finally, immune cell-
specific CD138 expression could be assessed in 151/154
(98.1 %) samples from primary tumours, in all 34 metas-
tases and in 34/38 (89.5 %) samples from fallopian tubes,
whereas tumour-specific expression of CD138 was quan-
tifiable in 151 (98.1 %) of the primary tumours and in 30
(88.2 %) of the metastases.
Fig. 1 Immunohistochemical images of IGKC, CD20 and CD138 staining in fallopian tubes, primary and metastatic epithelial ovarian cancer.
Sample images (40X magnification) representing immunohistochemical expression of IGKC (first row), CD138 (second row) and CD20 (third row),
described as core score, i.e. a multiplier of intensity (0–3) and fraction of staining; left column representing negative CS, middle column
intermediate CS and right column high CS
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The expression of the three biomarkers did not differ
significantly between primary tumours and metastases,
however; both IGKC and CD138 expression was found
to be significantly higher in primary tumours than in fallo-
pian tubes (p = 0.004 and p = 0.001, respectively) (Fig. 2).
Interrelationship of IGKC, CD20 and CD138 expression
and associations with clinicopathological factors
There were significant associations between expression
of the three markers; IGKC and CD20 (p = 0.001), IGKC
and CD138 (p = 0.0017) and CD20 and CD138 (p = 0.036)
(Table 1). Furthermore, there was a significant inverse asso-
ciation between expression of CD20 and PIGR (p = 0.039).
Both CD20 and CD138 expression were associated with
high-grade tumours (p = 0.032 and p = 0.030, respectively),
whereas no significant association was found between
IGKC expression and differentiation grade. None of the
three investigative biomarkers correlated significantly with
age or clinical stage. Only IGKC expression was found to
differ significantly between histological subtypes, with
higher expression in clear cell type tumours (p = 0.026)
(Table 2). Finally, higher CD20 expression was more often
present in KRAS wild-type tumours (p = 0.027).
Prognostic significance of IGKC, CD20 and CD138
expression
For IGKC expression, CRT analysis established an opti-
mal cut-off point at CS ≤ 28.5, which was used to stratify
cases into groups of low (CS ≤ 28.5, n = 128) and high
expression (CS > 28.5, n = 23), respectively (Additional
file 1). Using the same method, cases were divided into
groups of low (CS ≤ 0.75, n = 93) and high CD20 expres-
sion (CS >0.75, n = 61). Neither IGKC nor CD20 expres-
sion showed any significant association with OS or OCSS
in Kaplan-Meier analysis (data not shown).
Similarly, immune cell-specific CD138 expression was
dichotomized into groups of low (CS ≤ 2.25, n = 51) and
high expression (CS >2.25, n = 100). Kaplan-Meier analysis
revealed a significant association between high immune
cell specific expression of CD138 and poor OS (p = 0.001)
as well as OCSS (p = 0.002) (Fig. 3). These associations
were also present in the subgroup of serous carcinoma
(data not shown). Univariable Cox regression analysis con-
firmed the relationship between high CD138 expression
and a decreased OS (HR = 2.20; 95 % CI 1.34-3.55; p =
0.001) as well as OCSS (HR = 1.95; 95 % CI 1.28–2.98;
p–0.002). These associations remained significant in
multivariable analysis, adjusted for age, stage and grade
for OS (HR = 2.28; 95 % CI 1.39–3.75; p = 0.001) and
OCSS (HR = 1.97; 95 % CI 1.27–3.05; p = 0.002).
We also examined the prognostic impact of a com-
bined variable of CD138 and CD20 expression. As
shown in Additional file 2, cases with high expression of
both CD138 and CD20 had a significantly poorer OS in
Fig. 2 Distribution of IGKC, CD20 and CD138 expressions in fallopian
tubes, primary tumours and metastases. Box plot visualising the
staining distribution of (a) IGKC (b) CD20 and (c) CD138 in fallopian
tubes, primary tumours and metastases. CD20 expression is
described as core score, i.e. a multiplier of fraction in estimated
percentage and intensity (0–2) of staining
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Kaplan-Meier analysis (p = 0.001), as compared to refer-
ence cases with CD138 low/CD20 low immune cell-
specific expression, as did CD138 high/CD20 low cases
(p = 0.003). Univariable Cox regression analysis con-
firmed this relationship (HR = 2.86; 95 % CI 1.50–5.44;
p = 0.001 for CD138 high/CD20 high and HR = 2.51;
95 % CI 1.34–4.70; p = 0.004 for CD138 high/CD20 low
cases). However, these associations did not remain sig-
nificant in adjusted analysis (data not shown). OCSS
showed similar trends to OS between the reference
group, CD138 high/CD20 high, and CD138 high/CD20
low (data not shown).
Tumour-specific CD138 expression did not correlate
significantly with prognosis (data not shown).
Discussion
Multiple studies have previously described associations
between infiltrating immune cells, prognosis and treat-
ment response in cancer; nonetheless, the clinical rele-
vance has most often been attributed to the T-cell linage
[24]. In EOC, the infiltration of T-lymphocytes has been
associated with markedly prolonged survival in multiple
studies [15, 25–29], while the prognostic impact of
tumour-infiltrating B cell and plasma cell markers is
more unexplored. This study comprehensively analysed
the prognostic significance of B-cell and plasma cell
markers in EOC.
To the best of our knowledge, this is the first report to
describe the prognostic impact of immune cell-specific
CD138 expression in EOC. Interestingly, we found high
immune cell-specific CD138 expression to be an
independent prognostic marker for shorter survival in
EOC. This is in line with previous findings in breast can-
cer [30], but in contrast with the study in non-small cell
lung cancer by Lohr et al., wherein high immune cell-
specific CD138 expression was found to correlate with
improved patient outcome [9].
Chronic inflammation is known to be a major factor
in the development and progression of EOC, incurred
by e.g. ovulation, [31] and previous findings demonstrate
local activation of B-cells to cause neoplasms [32]. Mo-
hammed et al. lay forward a plausible hypothesis for the
prognostic impact of CD138+ TILs based on these facts,
whereby a large CD138+ subpopulation is suggested to
suppress T-cell response or to promote tumour progres-
sion by nurturing an inflammatory microenvironment [30].
Further, B-cells are able to attenuate chemotherapy
response in squamous cell carcinoma [33] by fostering
angiogenesis and inhibiting T-cell response. In a mouse
model, B-cells have been shown to antagonize the
tumour suppressing effects of chemotherapy and T-cells
[34]. As the vast majority of the patients included in the
present study received chemotherapy, the reduced sur-
vival rates of patients with tumours displaying a high
CD138+ TIL count may be explained by the interference
of B-cells and plasma cells in chemotherapy response.
Aforementioned findings and the findings of the present
study highlight the janus-faced role of the humoral
immune system and the potential of using B-cells as
therapeutic targets in cancer treatment.
CD138 has, in contrast to IGKC, a broader staining
profile with reactivity in tumour cells and tumoural
stroma besides plasma cells. Several studies have reported
high stromal- or tumour-specific CD138 to be associated
with poor patient outcome in various types of cancer, in-
cluding EOC [35–37] and Rousseau et al. described
CD138 as a promising new target for immunotherapy in
metastatic breast cancer [38]. This could be explained by
the biological functions of CD138, which have been shown
to affect several steps in tumour progression and to facili-
tate metastasis [39] and increased chemotherapy resist-
ance [40]. On the other hand, Kusumoto et al. reported
loss of epithelial CD138 to correlate with improved prog-
nosis in EOC [12]. In the present study, however, stromal
expression was not accounted for and tumour-specific
CD138 expression was not prognostic. Moreover CD138
expression was found be significantly higher in KRAS
wild-type tumours. This association is well in line with the
previously demonstrated association of KRAS wild-type
with high tumour grade and reduced survival in the herein
investigated cohort [23].
In addition, we found a significant correlation between
expression of CD138 and IGKC, consistent with previ-
ous research indicating also the reliability of the immu-
nohistochemical markers for the plasma cells lineage [9].
Table 1 Interrelationship between IGKC, CD20 and CD138
expression in primary tumours
Entire cohort Serous carcinomas
IGKC CD20 CD138 PIGR IGKC CD20 CD138 PIGR
IGKC
R 0.257** 0.196* 0.008 0.237* 0.113 −0.027
p 0.001 0.017 0.923 0.025 0.297 0.805
n 151 148 150 89 87 89
CD20
R 0.257** 0.171* −0.167* 0.237* 0.126 −0.083
p 0.001 0.036 0.039 0.025 0.244 0.439
n 151 151 153 89 88 90
CD138
R 0.196* 0.171* −0,087 0.113 0.126 0.100
p 0.017 0.036 0.292 0.297 0.244 0.356
n 148 151 150 87 88 88
R = Spearman’s correlation coefficient, p = p-value, n = number of cases
available for analysis. IGKC = immunoglobulin kappa c; PIGR = polymeric
immunoglobulin receptor. *significance at 5 % level, ** significance at 1 %
level. The analysis are based on cytoplasmic score (multipliers of staining
intensity and fraction) for PIGR and core score for IGKC, CD20 and CD138
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Although IGKC should be a more convenient marker
for biomarker studies related to plasma cells [41], this
study found no significant prognostic impact of IGKC
expression. These findings are analogous with what
Schmidt and colleagues previously demonstrated at the
gene expression level in 426 cases of EOC [10]. In non-
small cell lung cancer the prognostic value of IGKC and
CD138 was found to be similar [9] but although IGKC is
a more specific marker for plasma cells, the prognostic
value of IGKC and CD138 may differ in different types
of cancer, depending on the microenvironment and pos-
sibly also in relation to adjuvant chemotherapy. Further
studies are warranted to elucidate the prognostic and
potential predictive value of CD138 and IGKC in EOC.
In high-grade serous EOC, high infiltration of CD20+
B cells has been associated with prolonged survival [15],
an observation that was not confirmed in our study.
Nielsen et al. demonstrated CD20+ and CD8+ TILs to
work cooperatively to mediate anti-tumour immunity,
leading to markedly prolonged patient survival [14]. Fur-
ther, Kroeger et al. showed that, in high-grade serous
EOC, plasma cells were associated with infiltration of
other lymphocyte population such as CD8+ cells and an
active cytotoxic anti-tumour response [42]. In addition,
the study demonstrated that the prognostic impact of
CD8+ cells was only evident in tumours with infiltration
of other types of lymphocyte populations such as CD20+
cells and plasma cells. The present study only examined
the expression and prognostic impact of B cells and
plasma cells, but it would be also of interest to examine
the interrelationship and prognostic impact of various
subsets of T-cells and B-cells in future studies. Of note,
in the present study, we demonstrated high B-cell and
plasma cell infiltration in combination to be an indicator
of poor prognosis, although not independent of other
prognostic factors.
It can be surmised that CD20+ TILs primarily func-
tion as antigen presenting cells and thus need cooper-
ation with the cellular immune response to effect
tumour progression. CD20 expression was found to cor-
relate significantly with high tumour grade. Furthermore,
CD20 expression was revealed to have an inverse rela-
tionship with tumour-specific expression of PIGR, a re-
ceptor that binds polymeric immunoglobulin molecules
Table 2 Associations between IGKC, CD20 and CD138 expression and clinicopathological and investigative factors
Factor IGKC expression mean/median (range) CD20 expression mean/median (range) CD138 expression mean/median (range)
Age
p 0.886 0.879 0.067
≤Median 12.34/ 8.75 (0.00–70.00) 3.16// 0.00 (0.00–40.00) 9.24/ 5.00 (0.00–60.00)
>Median 13.25/7.00 (0.00–105.00) 2.43/0.00 (0.00–27.00) 16.53/6.00 (0.00–100.00)
Histological subtype
p 0.026 0.099 0.088
Serous 12.55/7.00 (0.00–1 05.00) 3.32/0.25 (0.00–40.00) 12.15/5.25 (0.00–75.00)
Endometroid 8.92/4.50 (0.00–60.00) 2.24/0.00 (0.00–27.00) 13.76/5.00 (0.00–80.00)
Mucinous 10.40/7.50 (0.00–32.00) 1.08/0.00 (0.00–10.00) 8.25/1.25 (0.00–70.00)
Others 27.81/20.00 (0.00–70.00) 2.05/0.00 (0.00–18.00) 15.89/11.00 (0.00–100.00)
Differentiation grade
p 0.403 0.032 0.030
Low 13.50/7.00 (0.00–105.00) 3.00/0.00 (0.00–27.00) 13.47/6.75 (0.00–100.00)
High 11.14/7.00 (0.00–70.00) 2.35/0.00 (0.00–40.00) 11.69/2.50 (0.00–80.00)
Clinical stage
p 0.443 0.880 0.388
I 14.92/8.25 (0.00–70.00) 3.17/0.00 (0.00–20.00) 12.38/5.00 (0.00–80.00)
II 9.05/7.00 (0.00–32.50) 3.72/0.00 (0.00–27.00) 6.33/5.00 (0.00–30.00)
III 12.64/7.25 (0.00–70.00) 2.38/0.00 (0.00–40.00) 14.64/7.00 (0.00–70.00)
IV 15.93/7.25 (0.00–105.00) 1.81/0.00 (0.00–17.00) 16.83/5.00 (0.00–100.00)
KRAS mutation status
p 0.076 0.027 0.135
Wild-type 13.26/7.50 (0.00–105.00) 3.08/0.00 (0.00–40.00) 13.29/6.00 (0.00–100.00)
Mutated 9.50/1.00 (0.00–70.00) 0.68/0.00 (0.00–10.00) 10.53/2.50 (0.00–70.00)
IGKC = immunoglobulin kappa C. The analysis of biomarker expression was based on a multiplier of staining intensity and fraction of immune cell staining
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at the surface of epithelial cells. High expression of PIGR
has been demonstrated to correlate with an improved
patient outcome in several cancer forms including EOC
[16, 43–46] and, speculatively, this may be attributed to
a negative regulatory function of PIGR on B-cell TILs,
or vice versa.
Conclusions
In conclusion, we have analysed several markers of the
humoral immune response in EOC and identified im-
munological subgroups that independently correlate
with clinical outcome. This results from this study
supplement and extend the current knowledge on the
immune landscape in EOC, and may thus provide
further information to enable the development of immune
modulatory treatment options.
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